Recursion Pharmaceuticals (NASDAQ:RXRX) Trading 6.3% Higher – Here’s Why

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) traded up 6.3% during trading on Tuesday . The company traded as high as $3.41 and last traded at $3.4550. 2,586,184 shares were traded during mid-day trading, a decline of 86% from the average session volume of 18,141,520 shares. The stock had previously closed at $3.25.

Analyst Ratings Changes

Several brokerages recently issued reports on RXRX. Weiss Ratings reissued a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a report on Friday, July 17th. JPMorgan Chase & Co. dropped their target price on Recursion Pharmaceuticals from $11.00 to $10.00 and set an “overweight” rating on the stock in a research report on Thursday, April 30th. Morgan Stanley set a $5.30 price target on shares of Recursion Pharmaceuticals in a report on Monday, August 17th. Wall Street Zen lowered shares of Recursion Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 8th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $8.00 price objective on shares of Recursion Pharmaceuticals in a research report on Thursday, May 7th. Two equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $8.06.

Recursion Pharmaceuticals Stock Down 2.0%

The firm has a market cap of $1.87 billion, a price-to-earnings ratio of -3.36 and a beta of 1.03. The stock’s 50 day moving average is $3.31 and its 200 day moving average is $3.35. The company has a quick ratio of 5.03, a current ratio of 5.03 and a debt-to-equity ratio of 0.01.

Recursion Pharmaceuticals (NASDAQ:RXRX) last posted its quarterly earnings data on Wednesday, August 5th. The company reported ($0.25) earnings per share for the quarter, missing the consensus estimate of ($0.24) by ($0.01). The business had revenue of $7.67 million for the quarter, compared to the consensus estimate of $10.97 million. Recursion Pharmaceuticals had a negative net margin of 945.94% and a negative return on equity of 50.41%. During the same quarter last year, the business posted ($0.41) EPS. Analysts forecast that Recursion Pharmaceuticals, Inc. will post -0.92 EPS for the current year.

Insiders Place Their Bets

In other Recursion Pharmaceuticals news, CEO Najat Khan sold 23,588 shares of the company’s stock in a transaction dated Friday, June 5th. The stock was sold at an average price of $3.58, for a total value of $84,445.04. Following the transaction, the chief executive officer directly owned 2,175,796 shares of the company’s stock, valued at $7,789,349.68. This represents a 1.07% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Blake Borgeson sold 40,000 shares of the firm’s stock in a transaction that occurred on Tuesday, July 7th. The shares were sold at an average price of $3.96, for a total transaction of $158,400.00. Following the transaction, the director directly owned 6,218,287 shares in the company, valued at approximately $24,624,416.52. The trade was a 0.64% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 131,937 shares of company stock worth $478,874 in the last quarter. 6.65% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Recursion Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of the business. Brighton Jones LLC raised its holdings in Recursion Pharmaceuticals by 49.4% during the fourth quarter. Brighton Jones LLC now owns 20,261 shares of the company’s stock valued at $137,000 after buying an additional 6,699 shares in the last quarter. Royal Bank of Canada boosted its stake in shares of Recursion Pharmaceuticals by 627.6% during the 1st quarter. Royal Bank of Canada now owns 269,013 shares of the company’s stock worth $1,423,000 after acquiring an additional 232,038 shares in the last quarter. AQR Capital Management LLC bought a new stake in shares of Recursion Pharmaceuticals during the 1st quarter worth about $890,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of Recursion Pharmaceuticals by 7.5% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 177,434 shares of the company’s stock valued at $953,000 after acquiring an additional 12,372 shares during the last quarter. Finally, Focus Partners Wealth acquired a new position in shares of Recursion Pharmaceuticals during the 1st quarter valued at about $77,000. Institutional investors and hedge funds own 89.06% of the company’s stock.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company’s proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.

At the core of Recursion’s offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.